SCHEMBL6151705

SCHEMBL6151705

COC(=O)c1ccc(Oc2ccc(C(F)(F)F)cc2)c(CN(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 12/20 0.64
SLC6A2 P23975 7/20 0.64
SLC6A3 Q01959 5/20 0.60
SCN9A Q15858 1/20 0.52
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.49
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HRH3 Q9Y5N1 2/20 0.48
HTR2A P28223 2/20 0.47
KCNH2 Q12809 2/20 0.47
MAPK1 P28482 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LSS P48449 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153170 0.82 SLC6A4 (0.67) SLC6A4SLC6A2SLC6A3ALDH1A1HRH3
SCHEMBL21628831 0.81 MAPT (0.55) MAPTKDM4ELMNAALDH1A1HPGD
SCHEMBL6152112 0.79 SLC6A4 (0.66) SLC6A4SLC6A2SLC6A3SCN9AMAPT
SCHEMBL6152684 0.78 SLC6A4 (0.68) SLC6A4SLC6A2SLC6A3SCN9AHTR2A
SCHEMBL1782842 0.77 LMNA (0.69) MAPTKDM4ELMNAHPGDMEN1
SCHEMBL19951264 0.77 MAPT (0.60) SLC6A4MAPTKDM4ELMNAALDH1A1
SCHEMBL6152604 0.77 SLC6A4 (0.71) SLC6A4SLC6A2SLC6A3SCN9AMAPT
SCHEMBL6151597 0.77 SLC6A4 (1.00) SLC6A4SLC6A2SLC6A3SCN9AALDH1A1
SCHEMBL3936831 0.76 NOTUM (0.55) SLC6A4SLC6A2KDM4ELMNAALDH1A1
SCHEMBL6151567 0.75 SLC6A4 (0.70) SLC6A4SLC6A2SLC6A3SCN9AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268396-B1 DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2005-07-20 EP disclosed
US-6448293-B1 TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. PFIZER INC. 2002-09-10 US disclosed
US-20020052395-A1 Diphenyl ether compounds useful in therapy ANDREWS MARK DAVID (GB) 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052395-A1 Diphenyl ether compounds useful in therapy CBR1, OGFR, CBR3 SLC6A4 2002/4885SLC6A2 1349/4885SLC6A3 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.